Frontlight ResearchEarly access
Not yet taking people in RomaniaPhase 1
Tests OJR520 safety in healthy adults and people with chronic kidney disease
Tests OJR520, a new medicine, in healthy adults and adults with kidney disease.
Key facts
- Who runs it
- Novartis Pharma AG
- Where
- Bucharest and Cluj-Napoca, RomaniaSee the 2 sitesAlso in 1 other country, 1 site
- Trial code
- EU 2025-520978-18-00
- U1111-1327-9750
- Registry title
- A Participant- and Investigator--Blinded, Placebo-Controlled, Randomized, Multipart, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants with Chronic Kidney Disease
- Status
- Not yet recruiting
- Phase
- Phase 1
- People taking part
- 44 people, planned
- Started
- 5 Feb 2026
- Expected to end
- 13 Mar 2027
- Type of study
- Interventional
- Record updated
- 20 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for healthy volunteers and for people with chronic kidney disease to test the safety and effects of a study drug called OJR520.
- Age
- 18 years or older
- Sex
- All sexes can join.
Where in Romania
Also in 1 other country, 1 site
- Arensia Clinics S.R.L.Bucharest, RomaniaNot yet recruiting
- Spitalul Clinic Judetean De Urgenta ClujCluj-Napoca, RomaniaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Plain-language title
- Tests OJR520 safety in healthy adults and people with chronic kidney diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 20 July 2026